走向乙型肝炎功能性治愈的HBsAg轨迹及关键分水岭  

HBsAg trajectory and key watersheds towards functional cure of hepatitis B

作　　者：梁携儿[1] 刘智泓[1] 李咏茵[1] 樊蓉[1] 侯金林[1,2] Liang Xieer;Liu Zhihong;Li Yongyin;Fan Rong;Hou Jinlin(Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou510515,China;the Institute of Liver Diseases,Guangzhou510515,China)

机构地区：[1]南方医科大学南方医院感染内科,广州510515 [2]广东省肝脏疾病研究所,广州510515

出　　处：《中华肝脏病杂志》2024年第11期961-964,共4页Chinese Journal of Hepatology

基　　金：国家重点研发计划(2022YFC2304800,2022YFC2303600)。

摘　　要：慢性乙型肝炎病毒(HBV)感染是全球重要的公共卫生问题。乙型肝炎功能性治愈的实现仍是临床亟待解决的热点和难点。现有的核苷(酸)类似物(NAs)可持续抑制HBV DNA,聚乙二醇干扰素α单药或联用NAs的治疗方案的功能性治愈率尚未满足临床需求。新机制HBV抗病毒药物,尤其小核酸新药,为乙型肝炎功能性治愈带来突破性进展。基于乙型肝炎表面抗原(HBsAg)多时间点纵向数据描绘功能性治愈轨迹的预测模型可指导临床治疗策略。不同HBsAg水平可作为关键分水岭辅助临床试验中受试者的筛选,从而优化对乙型肝炎患者的个性化管理。Chronic hepatitis B virus(HBV)infection remains a pivotal global public health concern.Attaining a functional cure for hepatitis B continues to be a hot and difficult issue that requires immediate attention in clinical practice.There are currently nucleos(t)ide analogues(NAs)that can persistently suppress HBV DNA;however,the functional cure rate of pegylated interferon alfa(PEG-IFN-α)alone or in combination with NAs has not yet met clinical needs.The research and development on novel mechanisms for HBV antiviral drugs,especially small nucleic acid drugs,has brought breakthroughs to the functional cure of hepatitis B.The functional cure trajectory mapping and its prediction model can guide the selection of clinical treatment strategies based on the longitudinal data for HBsAg at various time intervals.The personalized management of hepatitis B patients can be optimized by utilizing varying HBsAg levels as a key watershed to aid in the screening of subjects in clinical trials.

关 键 词：乙型肝炎 功能性治愈 乙型肝炎表面抗原 治疗 

分 类 号：R512.62[医药卫生—内科学]